84.98
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DXCM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$84.03
Aprire:
$84.49
Volume 24 ore:
704.55K
Relative Volume:
0.20
Capitalizzazione di mercato:
$33.32B
Reddito:
$4.15B
Utile/perdita netta:
$535.20M
Rapporto P/E:
63.42
EPS:
1.34
Flusso di cassa netto:
$575.20M
1 W Prestazione:
+0.24%
1M Prestazione:
+6.23%
6M Prestazione:
-2.42%
1 anno Prestazione:
-23.89%
Dexcom Inc Stock (DXCM) Company Profile
Nome
Dexcom Inc
Settore
Industria
Telefono
(858) 200-0200
Indirizzo
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Confronta DXCM con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
DXCM
Dexcom Inc
|
84.97 | 33.46B | 4.15B | 535.20M | 575.20M | 1.34 |
![]()
ABT
Abbott Laboratories
|
124.88 | 229.71B | 43.11B | 13.98B | 6.66B | 7.98 |
![]()
BSX
Boston Scientific Corp
|
103.78 | 154.35B | 17.55B | 2.03B | 2.72B | 1.37 |
![]()
SYK
Stryker Corp
|
393.19 | 149.60B | 23.22B | 2.86B | 3.58B | 7.40 |
![]()
MDT
Medtronic Plc
|
91.06 | 114.97B | 33.54B | 4.66B | 5.19B | 3.62 |
![]()
EW
Edwards Lifesciences Corp
|
76.52 | 45.92B | 5.54B | 4.18B | 623.10M | 7.00 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-06-16 | Iniziato | Truist | Buy |
2025-05-30 | Iniziato | Goldman | Buy |
2025-04-10 | Iniziato | Mizuho | Outperform |
2025-02-03 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
2025-01-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
2024-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
2024-07-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
2024-05-30 | Iniziato | Redburn Atlantic | Neutral |
2024-03-12 | Iniziato | RBC Capital Mkts | Outperform |
2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
2023-04-17 | Aggiornamento | Raymond James | Outperform → Strong Buy |
2023-03-29 | Iniziato | UBS | Buy |
2023-01-26 | Iniziato | Wolfe Research | Outperform |
2022-10-18 | Iniziato | Barclays | Equal Weight |
2022-10-12 | Iniziato | Jefferies | Buy |
2022-07-15 | Iniziato | Bernstein | Outperform |
2022-03-02 | Ripresa | BofA Securities | Buy |
2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
2022-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
2021-10-18 | Downgrade | Guggenheim | Buy → Neutral |
2021-07-21 | Ripresa | Cowen | Outperform |
2021-05-28 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
2021-05-25 | Iniziato | Barclays | Overweight |
2021-04-15 | Iniziato | Atlantic Equities | Overweight |
2021-01-06 | Aggiornamento | UBS | Neutral → Buy |
2020-10-02 | Downgrade | Wells Fargo | Equal Weight → Underweight |
2020-05-27 | Reiterato | Piper Sandler | Overweight |
2020-05-14 | Iniziato | Wells Fargo | Equal Weight |
2020-03-05 | Iniziato | Citigroup | Buy |
2019-11-07 | Reiterato | Canaccord Genuity | Buy |
2019-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
2019-10-23 | Iniziato | Stifel | Buy |
2018-11-28 | Iniziato | UBS | Neutral |
2018-10-19 | Aggiornamento | Goldman | Sell → Neutral |
2018-09-12 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
2018-08-02 | Reiterato | Canaccord Genuity | Buy |
2018-07-02 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
2018-06-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
2018-05-11 | Iniziato | BofA/Merrill | Buy |
2018-05-03 | Reiterato | Canaccord Genuity | Buy |
2018-04-04 | Iniziato | Goldman | Sell |
2018-04-04 | Iniziato | Guggenheim | Neutral |
2018-03-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
2018-01-04 | Downgrade | Northland Capital | Market Perform → Under Perform |
2017-09-28 | Reiterato | Wedbush | Outperform |
Mostra tutto
Dexcom Inc Borsa (DXCM) Ultime notizie
Is DexCom Inc. a good long term investmentUnmatched profit growth - jammulinksnews.com
What drives DexCom Inc. stock priceConsistent high-performance stocks - Autocar Professional
What analysts say about DexCom Inc. stockMassive portfolio appreciation - Autocar Professional
DexCom Inc. Stock Analysis and ForecastUnmatched profit potential - Autocar Professional
DexCom: Delivering Consistent Growth (NASDAQ:DXCM) - Seeking Alpha
Still Too Pricey? Dexcom’s Double-Digit Growth May Not Be Enough (DXCM) - Seeking Alpha
Are Medical Stocks Lagging DexCom (DXCM) This Year? - Yahoo Finance
Why This Beaten-Down Medical Device Stock Could Be Your Best Investment for the Next 5 Years - AOL.com
Dexcom recalls 19 models of glucose monitoring receivers - Modern Healthcare
Dexcom’s Recall of Certain CGM Receivers is Class I - Medical Product Outsourcing
Foletta sells Dexcom (DXCM) shares worth $234,216 - Investing.com Australia
Foletta sells Dexcom (DXCM) shares worth $234,216 By Investing.com - Investing.com Canada
FDA updates recall of certain Dexcom CGM speakers (DXCM) - Seeking Alpha
Assessing the Impact of Dexcom's Critical Device Recall on Its Market Position and Investor Sentiment - AInvest
Dexcom recalls glucose monitor receivers due to alert failure risk - Investing.com
Dexcom recalls glucose monitor receivers due to alert failure risk By Investing.com - Investing.com UK
Dexcom Unveils Season 4 Roster for Game-Changing NIL Program at Signing Day Camp Hosted by Mark Andrews - The News-Gazette
DexCom (DXCM) Target Price Raised by Mizuho Analyst | DXCM Stock News - GuruFocus
Analyst recommendations: Airbnb, Dexcom, Gitlab, AMD, Citigroup… - MarketScreener
Morgan Stanley Adjusts DexCom Price Target to $89 From $82, Maintains Equal Weight Rating - MarketScreener
Beyond The Numbers: 8 Analysts Discuss DexCom Stock - Benzinga
DexCom (DXCM) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
When Should You Buy DexCom, Inc. (NASDAQ:DXCM)? - 富途牛牛
How To Trade This 150% Gainer Chasing A Cure For Type 1 Diabetes - Benzinga
DexCom, Inc. (DXCM) Stock Analysis: Evaluating a 18.25% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Ravens’ Mark Andrews leads first Dexcom U Signing Day Camp, inspiring young athletes with diabetes - WMAR 2 News Baltimore
Johnson Fistel Continues Investigation on Behalf of DexCom, Inc. Shareholders - GlobeNewswire
DexCom Is Doubling Down on Its ‘Mistake.’ Why It’s Time to Buy the Stock. - Barron's
Dexcom Unveils Portrait Gallery to Portray Emotional Highs and Lows of Living With Diabetes on World Diabetes Day - Investegate
What You Need to Know Ahead of DexCom’s Earnings Release - MSN
What You Need To Know Ahead Of DexCom’s Earnings Release - Barchart.com
Oppenheimer Reaffirms DexCom Buy Rating Amid HHS Wearables Push - MSN
Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year? - Nasdaq
3 Reasons Growth Investors Will Love DexCom (DXCM) - Yahoo Finance
Dexcom Schedules Second Quarter 2025 Earnings Release and Conference Call for July 30, 2025 at 4:30 p.m. Eastern Time. - BioSpace
DexCom (DXCM) Leads Healthcare Sector Gains - GuruFocus
15 Best Fundamental Stocks to Buy According to Hedge Funds - Insider Monkey
Here's Why DexCom (DXCM) is a Strong Momentum Stock - Yahoo Finance
DexCom’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Why DexCom (DXCM) is a Top Growth Stock for the Long-Term - Yahoo Finance
Can DexCom’s Stock Keep Rising? - timothysykes.com
Abbott stock DexCom stock gain on RFK Jr. comments (DXCM) - Seeking Alpha
Dexcom shares U.S. report on CGM benefits for type 2 diabetes - MassDevice
DXCM's Access Gains and Operational Strength Offset Margin Pressures - TradingView
Dexcom EVP Brown sells $41k in shares - Investing.com
Diabetics at Risk: FDA Issues Highest-Level Recall on 2M Dexcom Devices Over 'Deadly Fault' - inkl
Dexcom Inc Azioni (DXCM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Dexcom Inc Azioni (DXCM) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Brown Michael Jon | EVP, Chief Legal Officer |
Jul 15 '25 |
Sale |
86.03 |
500 |
43,015 |
94,602 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):